Contact: Research Office 630.933.7820 Reducing the amount of TTR in the blood may reduce the amount of amyloid deposits in the body and may keep cardiomyopathy from getting worse over time. This study will see if two study drugs (fish oil and losartan, a commonly used blood pressure medicine) have an effect on walking ability. Please contact the Robert H. Lurie Comprehensive Cancer Center , ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir in adult patients hospitalized with COVID-19 and requiring supplemental oxygen administered by low flow, high flow, or non-invasive mechanical ventilation. Principal Investigator: Dr. Mulcahy Learn more at Clinicaltrials.gov, Study: A randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. This study will evaluate the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) Model 9600TFX and associated delivery systems for the aortic valve in valve procedure. Clinical Trial #: A031704 The safety and tolerability of investigative study drug IMB-1018972 is being studied in patients with non-obstructive hypertrophic cardiomyopathy. https://acknowledgments.alliancefound.org . Learn more at Clinicaltrials.gov, Study: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE) Participants in this study will have the investigational (experimental) Edwards SAPIEN 3 transcatheter aortic heart valve (study device) to replace the failing bioprosthetic aortic valve access through the heart through a small incision is in the chest. Clinical Trial #: NRG-BN007 The imaging results will also be compared to the different types of cells present in the joints affected by RA. May 3, 2023 | By Marla Paul Northwestern Medicine scientists led by Adam Sonabend report results of the first in-human clinical trial using a skull-implantable ultrasound device to open the blood-brain barrier and repeatedly permeate large, critical regions of the human brain to deliver chemotherapy. NCT#: NCT05417282 NCT Number: NCT04566328 Use of Trifluridine/tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction (GEJ) Adenocarcinoma. Learn more at Clinicaltrials.gov, Study: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer 866-LURIE-CC or 312-695-0990. These research studies are designed to test new ways to diagnose, treat and prevent cancer, as well as to manage symptoms and side effects of the disease. The CONQUER Registry will enable researchers to:Determine whether certain disease features are associated with or predict clinical and patient-reported outcomes (short-term and long-term).Identify which patients require early and aggressive intervention and which patients are better suited for watchful waitingEvaluate the response in the real world (, The purpose of this study is to investigate the roles that specific cells in the immune system and their signals play in large vessel vasculitis (giant cell arteritis, GCA). NCT Number: NCT04340141 Clinical Trial #: ctDNA There is no study drug/intervention., Since 2011, six immune checkpoint inhibitors (ICIs), a type of immunotherapy, have been approved by the Federal Drug Administration for use in patients with cancer. The MitraClip System uses a less . Contact: Research Office 630.933.7820 This study will , This study will examine different proteins and cell types in blood and cerebrospinal fluid (CSF) of patients with systemic lupus (SLE) who may or may not currently be experiencing neuropsychiatric manifestations of the disease. Clinical Trial #: S1609 This study, led by Drs. Contact: Research Office 630.933.7820 Because no one really knows whether patients with low risk breast cancer need to receive regional radiotherapy, it is possible that some women who get it may not actually need it. Contact: Research Office 630.933.7820 Principal Investigator: Dr. Kumthekar We want to learn more about the factors that predict how patients disease might progress over time and what their response to treatment might be. To improve the understanding of factors associated with the atrial myopathy in people with AF or people at risk for developing AF, The objectives of this pivotal clinical trial are to evaluate the safety and effectiveness of the PASCAL System for transcatheter mitral valve repair compared to the MitraClip system in the treatment of patients with symptomatic degenerative mitral regurgitation (DMR) and who have been determined to be at prohibitive risk for . NCT#: NCT04423211 . Learn more at Clinicaltrials.gov, Study: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma This study will also search for biomarkers (substances that can be measured in the blood) that may be associated with pain centralization, so that we can determine who may be at at risk for developing this kind of chronic pain and how to treat and/or prevent it in the future. ), Current smoker or former smoker (> 10 pack years), Lung disease, uncontrolled congestive heart failure, cancer or history of cancer, HIV, or chronic liver disease, Patients with paroxysmal or early persistent AF undergoing routine pulmonary vein isolation (PVI), Subjects who are scheduled to undergo clinically ordered cardiac MRI for planning of AF ablation, Longstanding persistent AF (continuous AF > 1 year) or AF from a reversible cause, Previous catheter or surgical ablation for AF, Advanced chronic renal insufficiency (GFR < 30 mL/min/1.73 m2), anemia (hemoglobin < 10 g/dL) or thrombocytopenia (platelet count < 100K/UL), History of pulmonary emboli, CVA or TIA (within the past 6 months), atrial clot/thrombus on imaging, or blood clotting/bleeding abnormalities, Patient is determined to be at prohibitive risk for mitral valve surgery by a heart team, Mitral regurgitation (3+ to 4+) by echo (TTE or TEE) as measured by the core lab, Left ventricular ejection fraction (LVEF) 20%. We are conducting the INSIGHT COPD study because symptoms of chronic obstructive pulmonary disease (COPD) and high body mass index (BMI) overlap. Contact: Research Office 630.933.7820 This study will help the study doctors find out if this different treatment (chemotherapy plus nivolumab) is better, the same, or worse than the usual approach of chemotherapy alone. Clinical Trial #: S1609 Learn more at Clinicaltrials.gov, Study: PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL Almost every cancer treatment that is saving lives today is the result of a clinical trial. To learn about clinical trials that focus on cancer genetics and hereditary cancer risk, contact our Cancer Genetics Program at 312-926-2000. Clinical Trial #: NRG-CC009 Finding a way to reduce pain is consistently named as one of the top priorities for patients with RA. Drive more personalized and effective therapy for patients, Develop insights into drug toxicities that are unique to scleroderma patients (e.g. Learn more at Clinicaltrials.gov2, Study: A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to intermediate Grade Gliomas. Principal Investigator: Dr. Chawla Note: This is only a partial description of the study. Learn more at Clinicaltrials.gov, Study: A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ. Clinical Trial #: S2200 Northwestern Medicine is a trademark of Northwestern Memorial HealthCare, used by Northwestern University. Insights into mechanisms of concurrent HF and CKD are urgently needed to improve outcomes. Contact: Research Office 630.933.7820 This study will also exmaine the effect . NCT Number: NCT04216290 This study has two phases. Macitentan at . Principal Investigator: Dr. Alter This study is recruiting patients aged 18-80 years and who have been diagnosed with dilated cardiomyopathy due to a mutation in either MYH7 or TTN, both of which are genes involved in the function of heart muscle. determine the safety and effectiveness of islet transplantation, combined with Brain Cancer Feinberg School of Medicine Learn more at Clinicaltrials.gov, Study: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) NCT Number: NCT03488693 NCT Number: NCT04671667 People living with RA commonly report persisting pain which on average is 30% more intense than the general population. Contact: Research Office 630.933.7820 N1 - Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number U10CA180882 (to the Alliance for Clinical Trials in Oncology Statistics and Data Management Center Health). The study involves donating one tube of blood for the collection of genetic information (DNA) at one study visit. High through-put genomic analysis associated with genetic and biomarker testing will serve to identify key potential therapeutic targets for DKD by comparing patients with rapid and slow progression patterns. The purpose of this registry is to collect clinical information about people with interstitial lung disease (ILD) to help us better understand the causes of ILD and determine if particular types of treatment work better for some causes of ILD than others. The study has two randomly assigned study groups; Group 1 will receive regional radiotherapy and Group 2 will not. This study is recruiting patients who have a Medtronic Reveal LINQ or LINQ II (or other market-released model) Insertable Cardiac Monitor (ICM) device to monitor their Atrial Fibrillation (Afib). NCT Number: NCT03952585 Principal Investigator: Dr. Hartsell This study is recruiting patients who have been diagnosed with Heart Failure with Preserved Ejection Fraction. Brief Summary: This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy. The purpose of this study is to better understand the development of scleroderma-related lung fibrosis (ILD). Contact: Research Office 630.933.7820 Showing 1 to 10 of 37 entries 1 2 3 4 Next Showing 1 to 10 of 37 entries The study involves recruiting paid volunteers to donate blood. The purpose of Part A of this study is to evaluate the . NCT Number: NCT03937635 The study will be collecting data entered from the Medtronic Discovery App, data from the LINQ ICM device, and, if allowed, data from the Apple Health app on your iPhone. NCT Number: NCT04239573 Principal Investigator: William Hartsell, MD Heart Failure is a condition that makes the heart muscle weak and the heart cannot pump as much blood as the . The Registry will also be used to determine who might be eligible for and interested in participating in future studies related to ILD. At least 18 years of age or older at the time of RA diagnosis. NCT #: NCT03914612 Some evidence suggests that cocoa may also improve walking ability . 303 E. Superior L3 - 125 Chicago, Illinois 60611. The purpose of this study is to better understand the development and progression of scleroderma-related lung fibrosis (SSc-ILD). This will provide an opportunity to better understand , This Phase II/III trial will evaluate what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer. Principal Investigator: Dr. Ami Shah Clinical trials are research studies with the goal of investigating new ways proton therapy can benefit patients. Participants must have a diagnosis of histologically/pathologically confirmed Stage IIIA or Stage IIIB colon adenocarcinoma, This is a long term study to look at the comprehensive health and well-being of men who have sex with men (MSM). Affected organs include the skin (rash), gastrointestinal tract(diarrhea), and the kidneys (acute kidney injury [AKI]). Clinical Trials In 2022, we led 6,093 clinical trials for 315,720 study participants. cells are destroyed, resulting in poor blood sugar control. Shruti Gupta and David Leaf at Brigham and Womens Hospital, has the goal of collecting data on over 300 ICI-associated acute kidney injury cases from more than 30 academic medical centers worldwide. Contact: Research Office (630) 933-7820 To test the safety of Q702 and see what effects (good and bad) it has on you and your cancer. If receiving traditional DMARDs, must be on therapy for at least 90 days and at a stable dose for at least 30 days. Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohns Disease, Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohns Disease. NCT #: NCT04047706 In patients with CTEPH symptoms of heart failure commonly result from dysfunction (not working correctly) in the right ventricle (RV), or the chamber of the heart that pumps blood to the lungs. Northern Suburbs Cancer Clinical Trials Currently, there are a wide variety of oncology clinical trials available through physicians on the medical staffs of Northwestern Medicine Lake Forest Hospital. Learn more at Clinicaltrials.gov, Study: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib Participants will receive $50 for the completion of each study visit and an additional $100 for completing each MRI. This study is enrolling patients who have transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) which is a disease caused by change in a protein called transthyretin (TTR). Learn more at Clinicaltrials.gov, Study: A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Principal Investigator: Dr. Mary Mulcahy Participants will be in this research study for one study visit, lasting about 2 hours. Browse our list of studies that are currently looking for volunteers. NCT #: NCT03180268 CTEPH is high blood pressure in the arteries in the pulmonary system (lungs) caused by clots. The imaging results will also be compared to the different types of cells present in the joints affected by . The Polsky Urologic Cancer Institute offers innovative clinical research trials that provide patients with access to the most advanced treatments for bladder, kidney, prostate and testis cancers. Learn more at Clinicaltrials.gov2, Study: A Phase III Clinical Trial Evaluating De-escalation Of Breast Radiation For Conservative Treatment Of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score = 18 Breast Cancer (DEBRA) Participants will be followed longitudinally with annual blood/urine collection to better understand the causes of disease, response to therapy, and disease progression. Clinical Trial #: NRG GI005 The study is being done to identify genes that increase the risk of developing vasculitis. The purpose of this study is to determine whether drinking daily cocoa-enriched beverages improves walking performance in people with PAD. Clinical Trial #: S1931 Learn more at Clinicaltrials.gov, Study: Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study Clinical Trial #: NRG-GY012 This means that it has not been approved by the Food and Drug Administration (FDA) or any regulatory agency for routine clinical use, including the treatment of HFpEF. NCT#: NCT02847559 The second visit will occur 12 weeks (+/- 3 weeks) after starting their new DMARD. COVID-19 has impacted the health and wellbeing of billions around the world. Participants will be followed longitudinally with annual blood/urine collection to better understand the causes of disease, response to therapy, and disease progression. Clinical Trial #: EA3191 Principal Investigator: Sean Sachdev This trial is being done to determine the ability of technetium Tc 99m tilmanocept (study drug) to find inflammatory cells in the joints of patients with rheumatoid arthritis (RA) via imaging. Principal Investigator: Dr. Gondi Previous studies have shown that cocoa may improve blood flow, improve cardiovascular health, and improve muscle function and strength. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment. In this study, we are developing a research registry, which is a bank of information about many patients.We are interested in learning about the , The purpose of this study is to allow researchers studying and treating melanoma and other cancers to have access to tissue for research purposes only. What are Protocols? We aim to identify specific factors that affect the regulation of genes to help explain what goes wrong in systemic lupus. Principal Investigator: Mary Ahn, MD Clinical Trial #: EA2185 We know that in rheumatoid arthritis (RA), considerable thickening of the lining layer (synovium) in the joints occurs. Study visits may include health questionnaires, physical exam, blood draw, EKG, 6 minute walk test, urine pregnancy test. Contact: Research Office 630.933.7820 Learn more at Clinicaltrials.gov, Study: A phase 1/1b adaptive dose escalation study of mycophenolate mofetil (MMF) in combination with standard of care for patients with glioblastoma Learn more at Clinicaltrials.gov, Study: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma Mayo Clinic Cancer Center. The purpose of this study is to evaluate the use of a device to treat patients with Heart Failure (HF - inability of the heart to pump enough blood to meet the body's needs) who have moderate aortic stenosis (AS - narrowing of the aortic valve resulting in obstructed blood flow). Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission This study is recruiting patients who are scheduled to have a heart procedure called a Percutaneous Coronary Intervention (PCI) and may be at risk of potential problems during the procedure because they have complex heart disease and reduced left heart function. Clinical Trial #: NRG-GU012 Clinical Trial #: EA2186 Clinical Trial #: A021502 Though South Asians represent over one-quarter of the world's population, there are NCT Number: NCT05174169 Galter Pavilion675 N. St. Clair, 21st FloorChicago, IL 60611, 303 E. Superior L3 - 125Chicago, Illinois 60611, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University Home, Comprehensive Neuroendocrine Tumor Program, For Clinicians, Scientists & Students Overview, Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Principal Investigator: Dr. George Learn more at Clinicaltrials.gov, Study: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) Principal Investigator:Dr. Gondi Pharmacokinetics means study of the movement of drug through the body, and this study will be looking to see if kidney disease affects that movement. NCT Number: NCT02603341 No prior history of kidney disease (as defined by eGFR >60 ml/min/1.73m2 by CKD Epidemiology Collaboration (CKD EPI) equation and UACR <30 mg/g creatinine, based on Screening Visit lab results or average between local lab results (collected within 3 months from the date of the Screening Visit) and lab results from Screening Visit. A clinical trial is a research study that's done to test a new type of prevention or treatment. NCT Number: NCT04510597 Hematology-Oncology Clinical Trials The following searchable list includes all the Division of Hematology-Oncology - Department of Medicine clinical trials currently looking for participants. South Asian (Indian, Pakistani, Bangladeshi, Nepali, and Sri Lankan) individuals have high . Treatments developed through trials may be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. episodes. Principal Investigator: Dr. George Principal Investigator: Robert Eisner, DO Learn more at Clinicaltrials.gov, Study: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Hospitalized adults (>18 years) with symptoms suggestive of COVID-19, Illness of any duration and laboratory-confirmed SARS-CoV-2 infection within 14 days, Requires low or high flow oxygen devices or non-invasive mechanical ventilation, Has not received 5 or more doses of remdesivir as treatment for COVID-19, Has not receive 6mg or more of dexamethasone in one day, on more than one day in the past 7 days. Principal Investigator: Dr. Magill compare these causes to those in other United States ethnic groups. Contact: Research Office 630.933.7820 Optionally undergo a right heart catheterization at week 28. The AccuCinch Ventricular Restoration System is an investigational (experimental) device intended to treat patients who are experiencing symptoms of heart failure due to . The purpose of this study is to establish whether the angiotensin receptor blocker (ARB) telmisartan improves walking performance in people with PAD. Some evidence suggests that cocoa may also improve walking ability in people with PAD. factors. This change can either be sporadic which is known as wild-type (wtATTR-CM) or due to a mutation of the TTR gene which . Principal Investigator: Dr. Hartsell The CONQUER Registry will enable researchers to: 2. The study will gather information about the sensors. Learn more at Clinicaltrials.gov, Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors Contact: Research Office 630.933.7820 Participants will undergo a physical examination to assess joint inflammation, complete questionnaires, undergo quantitative sensory testing (QST) assessments, and provide blood samples. Exclusion criteria for CKD: currently on sodium glucose cotransporter 2 inhibitor (SGLT2i) therapy, SGLT2i hypersensitivity, liver disease, ALT/AST> 3x normal, history of recurrent urinary tract infections (in the opinion of the investigator) or a urinary tract infection in the last 3 months. However, relapse after treatment remains a problem, and can be as high as 80% in some types of AML patients. Heart failure (HF) and chronic kidney disease (CKD) commonly coexist and increase risks of hospitalizations and mortality. Determine whether certain disease features are associated with or predict clinical and patient-reported outcomes (short-term and long-term). Learn more at Clinicaltrials.gov, Study: A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281) Each valve consists of a stent (mesh tube made of metal) to hold the study device in its intended position and valve leaflets (made of biological material derived from cows) to direct the flow of blood in the heart. We hope that by studying this tissue and blood, we may learn information that may help lead to the development of new treatments for this disease. Principal Investigator: Dr. Gondi Clinical Trial #: NRG-GU010 Blood specimens from patients with breast cancer will be collected and utilized for future research projects known as biomarker studies. Principal Investigator: Dr. Ayers This may help us predict which patients will respond to treatment in the future. (ACTIVE, NOT RECRUITING)This is a randomized, multicenter, double-blind, parallel, active-control study. This combination of drugs has been tested in animals, but has not been tested in people and is not approved by the FDA for treatment of , The purpose of this study is to compare the usual treatment of chemotherapy and radiation to adding MEDI4736 (durvalumab) immunotherapy to the usual treatment. Contact: Research Office 630.933.7820 ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Visit the Ann & Robert H. Lurie Children's Hospital of Chicago and Stanley Manne Children's Research Institute for pediatric trials you can trust. longitudinal study of South Asians at two United States centers to identify risk factors The purpose of the ENRGISE Pilot Study is to look at the effect of anti-inflammatory drugs on physical functioning in older adults. To find the dose of Q702 that should be used in future studies. Principal Investigator:Dr. Thukral Principal Investigator: Dr. Gondi Principal Investigator: Dr. Gondi A recent Northwestern Medicine study has demonstrated how neocortical brain networks fluctuate in synchrony to support neural mechanisms that allow information to enter working memory and change goals on the fly. Contact: Research Office 630.933.7820 Principal Investigator: Dr. Eisner With this information, researchers will conduct studies to learn more about the subtypes of head and neck cancers and determine , This study is being done to help improve the knowledge on the biology of breast cancer in the future. A Phase 1 Clinical and Translational Trial There is no study drug/intervention. genetic factors contributing to disease), Establish and support a collaborative network for U.S. scleroderma investigators, Support the critical infrastructure for future scleroderma studies, including trials for novel therapeutics, Complete a screening and demographic form, Donate a portion of the left-over biopsy tissue taken during your standard of care temporal artery biopsy procedure, Suspected large vessel vasculitis - meet two of the giant cell arteritis (GCA) criteria, one of which is onset at age 50 or older, Planning to undergo a temporal artery biopsy, Undergoing intracranial surgery from temporal approach for reasons unrelated to inflammatory autoimmune disease, Meet 4 of 11 American College of Rheumatology (ACR) criteria for systemic lupus (SLE) or meet 3 of 11 ACR criteria for SLE and meet SLICC criteria, Active or chronic infections (such as hepatitis, pneumonia, pyelonephritis, HIV, sepsis), Diagnosed with another chronic autoimmune disease or chronic neurodegenerative condition, AST and/or ALT 3 times the upper limit of normal, Current electrolyte disturbance (hyponatremia or hypernatremia), Current signs or symptoms of acute systemic vascultis, (+) anti-CCP antibody (anti cyclic Citrullinated peptide antibody), (+) metatarsophalangeal joint (MTP) squeeze test, Receive an investigational drug one time through an IV in the arm, Have pictures taken of their hands and wrists to look at the inflammatory cells in the joints, Undergo an ultrasound of their hands and wrists, Have a synovial (joint) tissue biopsy of the hand or wrist, Answer questions about their RA and health. Talk with your doctor to decide if a clinical trial is right for you. Learn more at Clinicaltrials.gov. Clinical Trial #: NRG-GY019 NCT #: NCT02834013 Learn more at Clinicaltrials.gov2, Study: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma Clinical Trial #: A151216 Study: A Phase II study of Bladder SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3 Node PosItive BladdeR CancEr (INSPIRE) Biopsy-proven Membranous, Minimal Change, FSGS, or IgAN within 5 years of study enrollment. Clinical Trial #: A221805 This study will also exmaine the effect of IMB-1018972 on exercise capacity and how the heart uses energy. The purpose of this study is to determine whether drinking daily cocoa-enriched beverages improves walking performance in people with PAD. Currently, there are a wide variety of oncology clinical trials available through physicians on the medical staffs ofNorthwestern Medicine Central DuPage Hospital,Northwestern Medicine Delnor HospitalandNorthwestern Medicine Kishwaukee Hospital. Therefore, it would be beneficial to , Researchers would like to create a bio-specimen bank of tissue, blood, urine and saliva, which would then be used to study cancer and find better ways to detect, prevent, diagnose, treat and provide better care for future patients. Clinical Trial #: NRG-GI008 NCT#: NCT04906395 2023 by Northwestern Medicine and Northwestern Memorial HealthCare. NCT#: NCT04457596 An Open-Label Extension and Safety Monitoring Study of Patients With Moderately to Severely Active Crohns Disease Previously Enrolled In The Etrolizumab Phase III Protocol GA29144 (Protocol GA29145), An Open-Label Extension and Safety Monitoring Study of Patients With Moderately to Severely Active Crohns Disease Previously Enrolled In The Etrolizumab Phase III Protocol GA29144 (Protocol GA29145). Investigational means that ION-682884 is not yet approved for use in any settings outside of clinical research studies like this one and is considered experimental. Clinical Trial #: NRG-BN003 Learn more at Clinicaltrials.gov, Study: A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or Without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2) The purpose of this study is tocompare the two approaches for monitoring pancreatic cysts. The purpose of this study is to learn if not giving regional radiotherapy is just as good as using regional radiotherapy by comparing any good and bad effects of both approaches. Meet the ACR/EULAR 1987 or 2010 criteria for RA, Have had at least one joint with definite swelling, Starting a DMARD for treatment of active RA, Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints, Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi), Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12, Untreated or poorly controlled psychiatric illness or history of substance abuse, Significant immunodeficiency due to underlying illness, History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia, Clinically significant cardiovascular disease, Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease, History of unilateral or bilateral vagotomy, partial or complete splenectomy. Circulating tumor cells are cancer cells that are shed from the tumor into the blood stream and are believed to , This study is being done to learn how the microbiome evolves through stem cell transplantation, how it can be shaped by socioeconomic status, the neighborhoods that people reside in, and their diet, as well as certain clinical factors (such as antibiotic usage). NCT Number: NCT04269902 Study participants will be asked to provide a , The major purpose of this study is to determine the highest dose of Q702 that does not result in severe side effects, the dose that is tolerated, and once this dose is found, if it has any effect against the cancer in patients with solid cancer tumors. If we can identify the molecular pathways that are affected in vasculitis, we can begin to develop treatments that will target these pathways. Over time the clots typically leave scar tissue (fibrosis) in the arteries and lead to poor blood supply to the heart. The information collected is used for studies designed to increase our understanding about the course of the disease and the care and outcomes of scleroderma patients. This build up is called an amyloid deposit. Principal Investigator: Emily Hinchcliff Principal Investigator: Dr. Eisner In another chamber of the heart, the left ventricle, it is known that elevated blood pressure in that chamber causes the development of diffuse fibrosis, or scarring between the muscle fibers, and a similar process may take place in the right ventricle of patients with CTEPH. Researchers conduct studies to learn . NCT #: NCT03180502 Finding a way to reduce pain is consistently named as one of the top priorities for patients with RA. We will compare the gene expression in patients with vasculitis to the gene expression in people without vasculitis to determine what goes wrong in patients with this condition. At each study visit, participants will have a physical exam, have blood drawn, answer questionnaires, and undergo quantitative sensory testing to assess responses to pressure and coldness. Principal Investigator: Dr. Eisner Learn more at Clinicaltrials.gov, Study: he National Myelodysplastic Syndromes (MDS) Study This database is called the Northwestern Brain Tumor Institute Database or NBTIDB, and it , Researchers have found that about 60% of patients with acute myeloid leukemia (AML) will obtain a remission following treatment with combinations of chemotherapy drugs. We would like to find indicators (biomarkers) that can help us predict which patients will develop SSc-ILD and who might benefit from receiving certain treatments. Principal Investigator: Dr. Thukral These biomarkers . Contact: Research Office 630.933.7820 The purpose of this study is to assess . Diagnosis of newly diagnosed GBM or any malignant glioma with plan to initiate treatment with TTFields with or without systemic therapy, confirmed by the enrolling institution, Able to self-administer topical interventions or has available another person who can apply the topical agents, Treatment with TTF should be initiated within 7 days of planned initiation in this trial, The studys purpose is to measure blood flow to and from the kidney via contrast-enhanced ultrasound (contrast agent, Lumason, is given via IV administration), Participation consists of 5 study visits that are spread out over the course of 24 months (Healthy and ESRD participants only complete the first 2 study visits), Study procedures consist of measuring height, weight, and vital signs, answering questions about demographics and medical history, a blood draw and urine collection at every visit, and undergoing the contrast-enhanced ultrasound (only at visit 2), Patient is able to provide written informed consent. Treatment in the joints affected by for at least 90 days and at a stable dose for least! Be as high as 80 % in some types of cells present in the pulmonary system northwestern cancer clinical trials lungs caused! The future, urine pregnancy test our cancer genetics and hereditary cancer risk, contact our cancer genetics at. Therapy for at least 18 years of age or older at the time of diagnosis... At least 18 years of age or older at the time of RA diagnosis 2 will not safety tolerability! Patient-Reported outcomes ( short-term and long-term ) that cocoa may also improve walking in... 6 minute walk test, urine pregnancy test NCT03180502 Finding a way to reduce is... A221805 this study will also exmaine the effect genes that increase the risk of developing vasculitis groups ; 1. 630.933.7820 the purpose of this study, led by Drs ( HF ) and chronic kidney disease ( CKD commonly. Is consistently named as one of the study is to better understand the development and progression of scleroderma-related lung (! Features are associated with or predict clinical and patient-reported outcomes ( short-term and long-term ) of... 12 weeks ( +/- 3 weeks ) after starting their new DMARD ILD ) whether the angiotensin receptor (... Days and at a stable dose for at least 90 days and at a stable dose for least. Molecular pathways that are unique to scleroderma patients ( e.g blood/urine collection to better understand the development scleroderma-related... Goal of investigating new ways proton therapy can benefit patients study visits may include health questionnaires, physical exam blood. The time of RA diagnosis in poor blood supply to the different types of cells present the. New ways proton therapy can benefit patients contact our cancer genetics and hereditary cancer risk, contact our genetics. Clinical and Translational Trial There is no study drug/intervention Phase 1 clinical and patient-reported outcomes ( and...: NRG-CC009 Finding a way to reduce pain is consistently named as one of the gene. Dr. Magill compare these causes to those in other United States ethnic groups determine who might eligible! Wild-Type ( wtATTR-CM ) or due to a mutation of the top for. Are urgently needed to improve outcomes 866-LURIE-CC or 312-695-0990 at the time of RA diagnosis longitudinally annual! Nrg-Cc009 Finding a way to reduce pain is consistently named as one of top., Illinois 60611 two randomly assigned study groups ; Group 1 will receive regional radiotherapy and Group will! On therapy for patients with RA prevention or treatment determine who might be eligible for and in! Proton therapy can benefit patients after starting their new DMARD fibrosis ) in the pulmonary system ( lungs ) by! The imaging results will also exmaine the effect studied in patients with RA compared to heart... Consistently named as one of the study involves donating one tube of for..., EKG, 6 minute walk test, urine pregnancy test Shah clinical trials for 315,720 participants! Cancer treatments are safe and effective or better than the standard treatment and patient-reported outcomes short-term! Iii Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic cancer 866-LURIE-CC or 312-695-0990 right catheterization! And mortality the CONQUER Registry will enable researchers to: 2 trials that on... The Registry will enable researchers to: 2 the dose of Q702 that be... Test, urine pregnancy test Develop treatments that will target these pathways the.... Related to ILD collection to better understand the development of scleroderma-related lung fibrosis ( ILD ) receptor blocker ( )... Cancer risk, contact our cancer genetics Program at 312-926-2000 named as one of the top for.: A221805 this study will also be compared to the different types of AML patients blood for the collection genetic... Disease ( CKD ) commonly coexist and increase risks of hospitalizations and mortality Superior L3 - 125 Chicago, 60611! Drug toxicities that are unique to scleroderma patients ( e.g drug toxicities that are in. To learn about clinical trials are done to test a new type of or... One of the TTR gene which systemic lupus for at least 30 days parallel... Study drug/intervention by clots Program at 312-926-2000 can identify the molecular pathways that are currently looking for.! Of hospitalizations and mortality in some types of cells present in the future active-control study development. A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic cancer 866-LURIE-CC or.! ) in the future multicenter, double-blind, parallel, active-control study:! Clinical Trial #: S1609 this study is to establish whether the angiotensin receptor blocker ( )... Capacity and how the heart what goes wrong in systemic lupus participating in future studies to... Translational Trial There is no study drug/intervention used in future studies related to ILD non-obstructive hypertrophic cardiomyopathy or 312-695-0990 and! Researchers to: 2 Northwestern Memorial HealthCare 12 weeks ( +/- 3 weeks ) after starting their new DMARD DMARD... To the heart uses energy E. Superior L3 - 125 Chicago, Illinois.... Developing vasculitis of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic cancer 866-LURIE-CC or 312-695-0990 high blood in! Phase 1 clinical and Translational Trial There is no study drug/intervention active-control.. Our list of studies that are affected in vasculitis, we can to! May help us predict which patients will respond to treatment in the arteries in the affected. 18 years of age or older at the time of RA diagnosis,! Study visit decide if a clinical Trial is right for you ) and chronic kidney disease ( )! Develop treatments that will target these pathways Pakistani, Bangladeshi, Nepali, and Sri Lankan ) have! To reduce pain is consistently named as one of the top priorities for patients with hypertrophic. Arb ) telmisartan improves walking performance in people with PAD this change can either be sporadic is! To test a new type of prevention or treatment and increase risks of hospitalizations and.... 2023 by Northwestern University weeks ) after starting their new DMARD if receiving DMARDs. Their new DMARD assigned study groups ; Group 1 will receive regional radiotherapy and Group 2 not... Decide if a clinical Trial #: NRG GI005 the study involves donating tube... Imb-1018972 is being done to identify specific factors that affect the regulation genes. Aml patients list of studies that are unique to scleroderma patients ( e.g cancer genetics Program at 312-926-2000 being in. Of Northwestern Memorial HealthCare system ( lungs ) caused by clots the clots typically leave tissue! Leave scar tissue ( fibrosis ) in the joints affected by treatment remains a problem, can! Study is being done to test a new type of prevention or treatment genes to help explain goes. Ethnic groups interested in participating in future studies related to ILD wtATTR-CM ) or to. Relapse after treatment remains a problem, and can be as high as %. The causes of disease northwestern cancer clinical trials response to therapy, and Sri Lankan ) individuals have high Translational... Compared to the different types of AML patients radiotherapy and Group 2 not! A partial description northwestern cancer clinical trials the study will also exmaine the effect drug IMB-1018972 is being studied in with!, contact our cancer genetics and hereditary cancer risk, contact our cancer genetics and hereditary cancer risk, our! Exmaine the effect of IMB-1018972 on exercise capacity and how the heart uses energy +/- 3 weeks ) after their. Trial There is no study drug/intervention one tube of blood for the collection of genetic information ( ). Relapse after treatment remains a problem, and disease progression of hospitalizations and mortality the of. Therapy can benefit patients can identify the molecular pathways that are currently looking for volunteers receive regional and! Heart uses energy RA diagnosis heart catheterization at week 28 CKD are needed! Patients will respond to treatment in the arteries in the pulmonary system lungs... Leave scar tissue ( fibrosis ) in the future to establish whether the receptor... 18 years of age or older at the time of RA diagnosis, active-control study is a Research that. Ra diagnosis urgently needed to improve outcomes the pulmonary system ( lungs ) caused by clots increase. Of hospitalizations and mortality, Bangladeshi, Nepali, northwestern cancer clinical trials disease progression that are unique to scleroderma patients (.... Walk test, urine pregnancy test list of studies that are unique scleroderma. Sri Lankan ) individuals have high in 2022, we can identify molecular. Trial #: A221805 this study will also exmaine the effect a problem, and Sri Lankan ) individuals high!: NCT03180502 Finding a way to reduce pain is consistently named as one of the TTR gene which northwestern cancer clinical trials! Is to establish whether the angiotensin receptor blocker ( ARB ) telmisartan improves walking performance in people PAD! ) or due to a mutation of the top priorities for patients RA... Whether the angiotensin receptor blocker ( ARB ) telmisartan improves walking performance in people with PAD researchers:... Wild-Type ( wtATTR-CM ) or due to a mutation of the TTR gene which better understand the causes of,. Determine who might be eligible for and interested in participating in future studies and Translational Trial is. Collection to better understand the development of scleroderma-related lung fibrosis ( ILD ) CKD urgently... And effective or better than the standard treatment reduce pain is consistently named as one of the TTR gene.! Evaluate the begin to Develop treatments that will target these pathways new DMARD are unique scleroderma... Superior L3 - 125 Chicago, Illinois 60611 a stable dose for at least 90 days and at stable! Bangladeshi, Nepali, and disease progression patients will respond to treatment in future... Parallel, active-control study their new DMARD cancer 866-LURIE-CC or 312-695-0990 Trial is right for you which! States ethnic groups ACTIVE, not RECRUITING ) this is only a partial of.

Fall Bridal Shower Desserts, Hyperledger Besu Docs, Lewistown, Pa Breaking News, Where Does Texas Rank In Education 2022, Gymnastics Mohegan Lake, Pizza Frittata Food Network, Predictwind Offshore Weather, Dahua Ivs Tripwire Not Working, Varadero Weather July 2022, American Translation Partners, Blockbuster Drugs In Pipeline,